Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
破译DNp63和MDSCs在TNBCs肿瘤促进和转移中的功能
基本信息
- 批准号:10407562
- 负责人:
- 金额:$ 35.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-26 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Aggressive courseAntibodiesBackBindingBiological AssayBloodBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineCASP8 and FADD-like apoptosis regulating proteinCASP8 geneCCL22 geneCXCL2 geneCancer EtiologyCell SurvivalCellsCessation of lifeChitinaseClinicClinicalCoculture TechniquesCombined Modality TherapyDataDevelopmentFeedsFoundationsFutureGenesGenomeGoalsHealthHeterogeneityHumanImmuneImmunocompetentImmunophenotypingImmunosuppressionImmunotherapyIn VitroInfiltrationKnockout MiceLabelMMP9 geneMalignant NeoplasmsMeasuresMediatingMolecularMonoclonal AntibodiesMouse Mammary Tumor VirusMusMyeloid-derived suppressor cellsNatural Killer CellsNatureNeoplasm Circulating CellsNeoplasm MetastasisNormal CellOncogenicPathway interactionsPatientsPlayPrimary NeoplasmProductionPrognosisPrognostic MarkerPropertyProteinsPublishingRecombinantsRegulationRoleSamplingShapesSignal TransductionT-LymphocyteTNF geneTNFRSF1B geneTestingTherapeuticTimeTransgenic OrganismsTumor BurdenTumor PromotionTumor VolumeTumor stageTumor-DerivedUnited StatesUp-RegulationWNT Signaling PathwayWomanangiogenesisbasebreast cancer progressioncancer cellcancer genomecancer stem cellcancer subtypeschemokinechemotherapyconditional knockoutdisease heterogeneityin vivoinhibitorknock-downmalignant breast neoplasmmortalitymouse modelneoplastic cellnoveloverexpressionperipheral bloodpre-clinicalreceptorrecruitresponsesmall hairpin RNAstem cell functionstemnesstargeted cancer therapytargeted treatmenttranscriptome sequencingtriple-negative invasive breast carcinomatumortumor growthtumor initiationtumor microenvironmenttumor progression
项目摘要
Project Summary
Breast cancer remains a major health threat and is the second leading cause of cancer-related death in
women in the United States. Treatment of triple negative breast cancer (TNBC) patients is particularly
challenging due to the heterogeneity of the disease and plasticity of the cancer cells. TNBC represents about
15% of all breast cancers and is a particularly aggressive subtype, with limited treatment options and very poor
prognosis. The plasticity and heterogeneity of TNBCs makes them difficult to target therapeutically. Mounting
evidence suggests that normal cells within the tumor microenvironment (TME) play an important role in
dictating tumor cell fate. Compared to the unstable genome of cancer cells, the stable genomes of normal cells
within the TME make them ideal targets for drug therapies that can be used in combination with therapies
targeting cancer cells. Immune cells within the TME play an essential role in tumor progression and
metastasis. Moreover, increased numbers of one subtype of immune cell, myeloid-derived suppressor cells
(MDSCs), in circulating blood correlates with clinical stage, metastatic tumor burden and increased numbers of
circulating tumor cells (CTCs), suggesting it may be a promising prognostic marker in breast cancer patients.
However, it is currently unclear if MDSCs are recruited to the TME of TNBC and/or if they contribute to tumor
progression and metastasis. Using human patient samples, we found increased numbers of MDSCs in TNBC
patient tumors compared to other breast cancer subtypes. Moreover, we found increased expression of Np63
in TNBC patient samples with a high degree of MDSC infiltration, raising the intriguing possibility that MDSC
recruitment and/or survival may be driven by Np63 expression in TNBC patients. In support, our published
and preliminary studies demonstrate that reducing the level of Np63 in TNBCs decreases tumor growth,
progression and metastasis and is associated with reduced MDSC infiltrate. Additionally, we showed reduction
of chemokine and Tumor necrosis Factor (TNF) pathway genes in Np63-KD TNBC cells compared to control
cells, thus identifying a potential pathways by which Np63+ TNBC cells may regulate chemokine-dependent
recruitment and TNF-mediated survival of MDSCs in TNBCs. Finally, we show that MDSCs can promote
cancer stem cell function of TNBC cells. Together, our data indicates a novel crosstalk between Np63+ TNBC
cells and MDSCs in TNBCs, which could promote the aggressive nature of TNBC tumors, thereby increasing
metastasis and mortality of patients. Based on these data, the goal of the current proposal is to delineate
a novel mechanism by which Np63+ TNBC cells mediated chemokine and TNF signaling promotes
MDSC infiltration and survival, which then feeds back to TNBC cells to promote cancer progression
and metastasis.
项目概要
乳腺癌仍然是一个主要的健康威胁,并且是癌症相关死亡的第二大原因
在美国,三阴性乳腺癌 (TNBC) 患者的治疗尤其重要。
由于疾病的异质性和癌细胞的可塑性,TNBC 具有挑战性。
占所有乳腺癌的 15%,是一种特别具有侵袭性的亚型,治疗选择有限且效果非常差
TNBC 的可塑性和异质性使其难以进行靶向治疗。
有证据表明肿瘤微环境(TME)内的正常细胞在
与癌细胞不稳定的基因组相比,正常细胞的稳定基因组决定了肿瘤细胞的命运。
TME 内的药物使它们成为可与疗法联合使用的理想靶点
靶向 TME 内的免疫细胞在肿瘤进展和治疗中发挥着重要作用。
此外,一种免疫细胞亚型——骨髓源性抑制细胞——的数量增加。
(MDSC),在循环血液中与临床分期、转移性肿瘤负荷和增加的数量相关
循环肿瘤细胞(CTC),表明它可能是乳腺癌患者的一个有前途的预后标志物。
然而,目前尚不清楚 MDSC 是否被招募到 TNBC 的 TME 中和/或它们是否有助于肿瘤
使用人类患者样本,我们发现 TNBC 中的 MDSC 数量增加。
与其他乳腺癌亚型相比,我们发现患者肿瘤中 Np63 的表达增加。
在具有高度 MDSC 浸润的 TNBC 患者样本中,提出了 MDSC 的有趣可能性
TNBC 患者中的 Np63 表达可能驱动招募和/或生存,我们发表的研究支持这一点。
初步研究表明,降低 TNBC 中 Np63 的水平可降低肿瘤生长,
此外,我们还发现 MDSC 浸润减少。
与对照相比,Np63-KD TNBC 细胞中趋化因子和肿瘤坏死因子 (TNF) 途径基因的变化
细胞,从而确定了 Np63+ TNBC 细胞调节趋化因子依赖性的潜在途径
最后,我们证明 MDSC 可以促进 TNBC 中 MDSC 的募集和 TNF 介导的存活。
TNBC 细胞的癌症干细胞功能 总之,我们的数据表明 Np63+ TNBC 之间存在新的串扰。
TNBC 中的细胞和 MDSC,可以促进 TNBC 肿瘤的侵袭性,从而增加
基于这些数据,当前提案的目标是描绘患者的转移和死亡率。
Np63+ TNBC 细胞介导的趋化因子和 TNF 信号传导促进的新机制
MDSC 浸润和存活,然后反馈给 TNBC 细胞,促进癌症进展
和转移。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rumela Chakrabarti其他文献
Rumela Chakrabarti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rumela Chakrabarti', 18)}}的其他基金
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
破译DNp63和MDSCs在TNBCs肿瘤促进和转移中的功能
- 批准号:
10555482 - 财政年份:2022
- 资助金额:
$ 35.81万 - 项目类别:
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
破译DNp63和MDSCs在TNBCs肿瘤促进和转移中的功能
- 批准号:
10672261 - 财政年份:2022
- 资助金额:
$ 35.81万 - 项目类别:
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
破译DNp63和MDSCs在TNBCs肿瘤促进和转移中的功能
- 批准号:
10174878 - 财政年份:2019
- 资助金额:
$ 35.81万 - 项目类别:
相似国自然基金
腺相关病毒载体介导的circ_12952基因治疗通过激活结直肠癌抗肿瘤免疫增强PD-1抗体疗效的机制研究及临床探索
- 批准号:82303073
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
聚合物囊泡靶向骨组织递送mRNA编码抗骨硬化蛋白单链抗体治疗骨质疏松的研究
- 批准号:82372442
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于抗原抗体相互作用的抗体定向虚拟设计与筛选
- 批准号:32370697
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CDK4/6抑制剂通过IFN/JAK/STAT1信号轴增强PD-1抗体抗肝细胞癌疗效的机制研究
- 批准号:82373313
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
P29单克隆抗体的3-羟基丁酰化修饰对其稳定性影响及提升抗泡型包虫病作用的研究
- 批准号:82360402
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
破译DNp63和MDSCs在TNBCs肿瘤促进和转移中的功能
- 批准号:
10555482 - 财政年份:2022
- 资助金额:
$ 35.81万 - 项目类别:
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
破译DNp63和MDSCs在TNBCs肿瘤促进和转移中的功能
- 批准号:
10672261 - 财政年份:2022
- 资助金额:
$ 35.81万 - 项目类别:
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
破译DNp63和MDSCs在TNBCs肿瘤促进和转移中的功能
- 批准号:
10174878 - 财政年份:2019
- 资助金额:
$ 35.81万 - 项目类别:
B-cell repertoires in chronic lymphocytic leukemia
慢性淋巴细胞白血病的 B 细胞库
- 批准号:
7585135 - 财政年份:2000
- 资助金额:
$ 35.81万 - 项目类别:
B-cell repertoires in chronic lymphocytic leukemia
慢性淋巴细胞白血病的 B 细胞库
- 批准号:
7849949 - 财政年份:2000
- 资助金额:
$ 35.81万 - 项目类别: